Cefepime: Mechanism, Spectrum, Resistance, and Clinical Use

Cefepime is a fourth-generation cephalosporin antibiotic that works by binding to proteins bacteria need to build their cell walls, ultimately causing the cells to burst and die. What sets it apart from older cephalosporins is a unique chemical structure that lets it slip through bacterial defenses more quickly and resist many of the enzymes bacteria use to destroy antibiotics. That combination of speed and stability gives cefepime an unusually broad reach, covering many gram-negative bacteria, including Pseudomonas aeruginosa, as well as a meaningful slice of gram-positive organisms.

How Cefepime Gets In and What It Does Once Inside

All cephalosporins kill bacteria by targeting penicillin-binding proteins, or PBPs, which are enzymes embedded in the bacterial cell membrane that stitch together the rigid mesh of the cell wall. When cefepime locks onto these PBPs, wall construction stalls, the bacterium swells, and lysis follows. In lab experiments with E. coli, cefepime showed particularly strong binding to PBP 3 and had more than a twenty-fold stronger affinity for PBP 2 compared to related drugs in the same generation. Against Pseudomonas aeruginosa, the picture shifts: all tested fourth-generation cephalosporins bound poorly to PBP 2 but showed excellent PBP 3 binding, which is the target most responsible for the filamentous growth and eventual death of that organism.¹

The reason cefepime reaches those PBPs so effectively comes down to its electrical charge. The molecule carries both a positive and a negative charge simultaneously, making it a zwitterion with a net neutral charge overall. That neutrality allows it to slip through the water-filled channels, called porins, in the outer membrane of gram-negative bacteria faster than third-generation cephalosporins can.² Once through the outer membrane, the same structural features give cefepime low affinity for many of the beta-lactamase enzymes lurking in the periplasmic space, plus high affinity for the PBP targets it needs to hit.³ In practical terms, rapid entry plus enzyme stability plus strong target binding is what makes cefepime a step up from drugs like ceftazidime or cefotaxime.

What Cefepime Covers

Cefepime’s spectrum is genuinely broad by cephalosporin standards. On the gram-negative side, it covers the major Enterobacterales (organisms like E. coli, Klebsiella, Enterobacter, and Proteus) and retains clinically useful activity against Pseudomonas aeruginosa. In a study of bacteria that had already developed resistance to third-generation cephalosporins, 84% were resistant to ceftazidime and 91% to cefotaxime, but only about 6% were resistant to cefepime. The resistant strains were all Pseudomonas isolates with exceptionally high levels of beta-lactamase activity.⁴

On the gram-positive side, cefepime covers methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci, but it does not work against methicillin-resistant S. aureus (MRSA) or enterococci. Surveillance data from North American hospitals spanning 1998 to 2003 showed cefepime was fully active against MSSA, with a susceptibility rate of 100%, and was about four-fold more potent than ceftazidime against those organisms.⁵ A separate study confirmed similarly good MSSA activity, with a lower MIC for cefepime compared to ceftazidime.⁶ That combination of gram-negative reach and gram-positive coverage is the main reason clinicians turn to cefepime as a workhorse empiric antibiotic in hospital settings.

How Bacteria Resist Cefepime

Cefepime is more stable than older cephalosporins against many common beta-lactamases, but it is far from immune. The main resistance mechanisms fall into a few categories, and they often stack on top of each other in the most problematic organisms.

Extended-spectrum beta-lactamases (ESBLs): These enzymes, common in E. coli and Klebsiella, can hydrolyze cefepime. Even when lab testing reports an ESBL-producing bacterium as susceptible to cefepime, clinical outcomes may be worse than with carbapenems. A propensity-matched study of patients with ESBL bloodstream infections found a trend toward nearly three-fold higher risk of death in those treated with cefepime compared with carbapenems, though the confidence interval was wide enough that the result was not statistically definitive.⁷ That finding has made many infectious-disease specialists cautious about relying on cefepime alone for serious ESBL infections.
AmpC beta-lactamases: Organisms like Enterobacter and Citrobacter freundii can produce chromosomal AmpC enzymes at high levels. Cefepime is more stable to AmpC than third-generation cephalosporins, but overwhelming enzyme production can still raise the drug’s MIC beyond the treatable range, as demonstrated by the exceptionally high beta-lactamase levels in cefepime-resistant Pseudomonas isolates.
Carbapenemases: Metallo-beta-lactamases (MBLs) like NDM and VIM destroy cefepime efficiently. KPC-type carbapenemases, while primarily targeting carbapenems, also raise cefepime MICs well above breakpoints in most isolates.
Porin loss and efflux pumps: Bacteria can reduce the number of outer-membrane porins through which cefepime enters, or they can actively pump the drug back out. In Klebsiella pneumoniae, disruption of the major porins OmpK35 and OmpK36 reduces cefepime’s ability to accumulate in the periplasm.⁸ Similarly, the acrAB efflux system and associated genes like tolC have been identified as major contributors to resistance in multidrug-resistant K. pneumoniae.⁹

In real clinical isolates, these mechanisms rarely work alone. A single strain of Klebsiella might carry an ESBL, have reduced porin expression, and overexpress an efflux pump simultaneously. That layering is what makes resistance increasingly hard to predict from a single laboratory test.

Where Cefepime Is Used in the Hospital

Cefepime has FDA-approved indications for pneumonia, urinary tract infections, skin and soft-tissue infections, and empiric therapy of febrile neutropenia. In practice, it has become one of the first-line options when a critically ill patient needs broad gram-negative coverage quickly, especially if Pseudomonas is a concern.

Febrile Neutropenia

Patients whose white blood cell counts drop dangerously low after chemotherapy are at high risk of life-threatening infection, and guidelines have long endorsed cefepime as monotherapy for the initial empiric treatment of febrile episodes. A prospective study in cancer patients found that cefepime monotherapy controlled about 83% of febrile neutropenia episodes without additional antibiotics, and the overall protocol success rate was above 90%.¹⁰ Studies in lung cancer patients showed response rates around 78% overall and 85% in lower-risk episodes.¹¹ A head-to-head comparison in patients with blood cancers found that cefepime, meropenem, and piperacillin-tazobactam produced similar response rates at day 3 and day 7, with no statistically significant differences among them.¹²

Hospital-Acquired Pneumonia

In ICU patients with ventilator-associated pneumonia, a randomized trial comparing cefepime (2 g three times daily) with imipenem-cilastatin found similar clinical responses: about 70% for cefepime versus 74% for imipenem-cilastatin in the evaluable population.¹³ That rough equivalence with a carbapenem is meaningful because using cefepime instead of a carbapenem preserves the carbapenem class for situations where nothing else works, which is a core principle of antibiotic stewardship.

Cefepime Versus Piperacillin-Tazobactam

One of the most common real-world decisions in hospital medicine is choosing between cefepime and piperacillin-tazobactam (“pip-tazo”) for an acutely ill patient. The large ACORN trial, published in JAMA in 2023, randomized over 2,500 hospitalized adults and found no significant difference in the primary outcome of severe kidney injury or death. About 7% of patients in each group developed stage 3 kidney injury, and death rates were comparable.¹⁴

The ACORN trial did surface one notable finding, though. Patients in the cefepime group experienced slightly fewer days alive and free of delirium and coma within the first 14 days. The difference was statistically significant but small in absolute terms, and it aligns with what is known about cefepime’s neurotoxicity risk. For clinicians, the takeaway was reassuring on the kidney front but a reminder to pay attention to neurological status when using cefepime in critically ill patients.

The Neurotoxicity Problem

Cefepime-induced neurotoxicity is an underrecognized complication that can be mistaken for stroke, septic encephalopathy, or worsening of the underlying illness. The drug appears to block GABA receptors in the brain, reducing the normal inhibitory signaling and tipping the balance toward excitation.¹⁵ Symptoms typically appear within 1 to 10 days of starting treatment. The most common presentation is delirium, reported in roughly 80% of cases, followed by myoclonus in about 40%, nonconvulsive status epilepticus in about 31%, overt seizures in 11%, and aphasia in about 9%.¹⁶

A retrospective study of 319 patients with available trough levels found that overall incidence of neurotoxicity was about 23%. Patients who developed neurological symptoms had median trough concentrations more than three times higher than those who did not. Reduced kidney function was the strongest risk factor: those with neurotoxicity had substantially lower estimated kidney filtration rates. No neurotoxic effects appeared below a trough of 7.7 mg/L, while levels at or above 38.1 mg/L always caused problems. In-hospital mortality was also higher in the neurotoxicity group, at about 35% versus 8% in those without symptoms.¹⁷ The practical lesson is straightforward: dose-adjust for kidney function, and when a patient on cefepime develops unexplained confusion or twitching, check drug levels and consider switching.

Dosing Strategies and Extended Infusions

Like all cephalosporins, cefepime’s effectiveness depends on how long the drug’s concentration stays above the MIC of the target organism during each dosing interval. In critically ill patients whose physiology can be unpredictable, pharmacokinetic studies have consistently shown that standard intermittent dosing sometimes falls short of optimal targets, especially for bacteria with higher MICs. A study modeling cefepime at 2 g every 8 hours as a 3-hour infusion in patients with ventilator-associated pneumonia estimated that this regimen achieved adequate exposure about 92% of the time when MICs were 8 µg/mL, but that probability dropped to about 50% at an MIC of 32 µg/mL.¹⁸

Extended infusions, where the same total daily dose is given over 3 to 4 hours per dose instead of the traditional 30 minutes, aim to keep drug levels above the MIC for a larger fraction of the dosing interval. A real-world comparison found that clinical outcomes were similar between extended and intermittent infusion strategies, but the extended approach used about a third less drug per day, cutting average daily medication cost by roughly half.¹⁹ Many hospitals have now adopted extended infusion as a default for cefepime, driven by pharmacodynamic logic and cost savings even as the mortality benefit remains difficult to demonstrate in trials.

Dosing becomes especially tricky in patients on continuous kidney replacement therapy (CRRT). The machines remove cefepime at variable rates depending on flow settings, and several simulation studies have shown that standard reduced doses recommended in package inserts often fall short. One study found that patients on CRRT with higher effluent flow rates needed 2 g every 8 hours or 1 g every 6 hours to hit pharmacodynamic targets, considerably more than guideline-recommended doses.²⁰ The tension is obvious: higher doses improve bacterial killing but increase neurotoxicity risk, and simulation studies have confirmed that optimal CRRT dosing for gram-negative infections carries a neurotoxicity probability that clinicians need to weigh carefully.²¹ Therapeutic drug monitoring, where trough levels are measured directly, is increasingly advocated to thread this needle.

New Partner Drugs That Extend Cefepime’s Reach

The rise of carbapenem-resistant organisms has pushed drug developers to pair cefepime with novel beta-lactamase inhibitors, essentially giving an old antibiotic new armor against enzymes that would otherwise destroy it. Three combinations are in advanced development or already approved.

Cefepime-Taniborbactam

Taniborbactam is a boronic-acid-based inhibitor that blocks both serine beta-lactamases (like KPC) and, unusually, some metallo-beta-lactamases (like NDM). In a phase 3 trial of complicated urinary tract infections, the combination achieved composite success in about 71% of patients compared to 58% for meropenem alone, a statistically significant difference that held up at late follow-up.²² Global surveillance data showed that adding taniborbactam dropped the cefepime MIC required to inhibit 90% of Enterobacterales isolates by more than 64-fold, and the combination inhibited over 96% of multidrug-resistant Enterobacterales and about 80% of multidrug-resistant Pseudomonas.²³ One interesting wrinkle is that while cefepime relies heavily on OmpK35 and OmpK36 porins to enter the bacterial cell, taniborbactam does not seem to depend on those same porins, meaning porin loss may not fully protect bacteria from the combination.⁸

Cefepime-Enmetazobactam

Enmetazobactam is a penicillanic acid sulfone inhibitor designed primarily to counter ESBLs and some class A carbapenemases. A randomized trial in complicated urinary tract infections and acute pyelonephritis found that cefepime-enmetazobactam was not only noninferior but actually superior to piperacillin-tazobactam for the combined outcome of clinical cure and microbiological eradication.²⁴ A systematic review of resistance profiles found that ESBL-producing Enterobacterales were overwhelmingly susceptible, with resistance proportions ranging from 0% to about 3%. Activity dropped considerably against KPC producers, where resistance ranged from roughly 37% to 58%, and was poorest against MBL producers: in one study, 99% of NDM-producing isolates were resistant.²⁵ So enmetazobactam is well-suited for ESBL infections but not a solution for the most resistant carbapenemase producers.

Cefepime-Zidebactam

Zidebactam is a non-beta-lactam inhibitor that both blocks beta-lactamases and directly binds PBP 2, giving it a dual mechanism. In a collection of 400 carbapenemase-producing Enterobacterales, cefepime-zidebactam showed high activity regardless of the specific carbapenemase involved, with 99% of isolates susceptible at a breakpoint of 2 mg/L. The cefepime-taniborbactam combination was similarly potent against OXA-48 and KPC producers but less active against MBL-producing isolates.²⁶ Zidebactam remains in clinical development, but the in vitro data suggest it may have the broadest reach of the three partners against carbapenemase-producing organisms.

Carbapenem-Resistant Pseudomonas and the Dose Ceiling

Even where cefepime technically retains activity against Pseudomonas, the story is more complicated than a susceptibility report might suggest. A global surveillance study of carbapenem-resistant P. aeruginosa isolates that still tested susceptible to cefepime found that MICs clustered at the high end of the susceptible range. Standard dosing was unlikely to maintain adequate drug levels, and pharmacodynamic modeling suggested that 6 g per day would be needed to achieve optimal kill profiles.²⁷ That is the maximum labeled daily dose, and as discussed above, pushing doses higher increases the chance of neurotoxicity. For clinicians treating carbapenem-resistant Pseudomonas, the question is whether cefepime alone can thread the gap between effective killing and brain toxicity, or whether a combination approach offers better odds.

Cross-Reactivity in Beta-Lactam Allergy

Patients with a history of penicillin allergy often worry about taking cephalosporins. The current understanding is that true cross-reactivity between penicillins and cephalosporins depends primarily on the similarity of their R1 side chains rather than on the shared beta-lactam ring. Cefepime’s R1 side chain is distinct from those of most penicillins and from cephalosporins like cephalexin or cefazolin that share side-chain structures with amoxicillin or ampicillin. In practice, allergists generally regard cefepime as low-risk for patients whose penicillin allergy is not a severe immediate hypersensitivity reaction, though formal allergy evaluation is still warranted for anyone with a history of anaphylaxis to a beta-lactam.